Freelancer ロゴ
ログイン 登録
プロジェクトを投稿する
探す
Article Writing
Business Plans
Data Entry
Finance
Research Writing
プロフィールカバー写真
あなたはをフォローしました
ユーザーのフォローエラー。
このユーザーはフォローを許可していません。
このユーザーをすでにフォローしています。
あなたのメンバーシッププランは、0 個のフォローのみ許可します。アップグレードは、 こちら。
のフォローを解除しました
ユーザーのフォロー解除エラー。
あなたはを推薦しました
ユーザーの推薦エラー。
何か問題が発生しました。ページを更新してもう一度お試しください。
メールの認証に成功しました。
ユーザーアバター

Corey D.

@coreyd5

0.0
0
0.0
0.0
0%

Helping build tech-enabled healthcare companies

$50 USD / 時間
・
のフラグ
United States (11:54 午前)
・
登録日: 11月 30, 2024
$50 USD / 時間
・
Innovative and results-driven executive with extensive experience in healthcare-focused leadership, corporate development, mergers and acquisitions (M&A), and strategic consulting. Proven track record of driving growth for companies ranging from startups to publicly traded organizations. Adept at identifying undervalued opportunities, building partnerships, and managing complex transactions. Expertise in business development, DTC marketing, operations and market research.
確認
Freelancer Data Entry Clerks United States
全て見る Data Entry Clerks 、 United States

ポートフォリオ

ポートフォリオ

12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
変更を保存しました
0.0 · 0 Reviews
レビュー
レビューがありません！
招待状の送信に成功しました！
ありがとうございます！無料クレジットを受け取るリンクをメールしました。
メールを送信中に問題が発生しました。もう一度お試しください。
Freelancer ロゴ Japan / 日本語
ヘルプ＆サポート
 フリーランサー
カテゴリー プロジェクト コンテスト フリーランサー エンタープライズ AI開発 メンバーシップ 優先フリーランサープログラム プロジェクト管理 ローカルジョブ Photo Anywhere ショーケース 開発者用API 認証を受ける デスクトップアプリ
 関連情報
当社について ご利用方法 セキュリティ 投資家 サイトマップ ストーリー ニュース チーム アワード プレスリリース Careers
 利用規約
プライバシーポリシー 利用規約 コピーライトポリシー 行動規範 手数料とその他費用
 パートナー
Escrow.com Loadshift Warrior Forum
 アプリ
Apple App Store のロゴGoogle Play ロゴ
クリップボードへのコピーが失敗しました、権限を調整してからもう一度お試しください。
クリップボードにコピーされました。
登録ユーザー 投稿された仕事の合計
Freelancer ® is a registered Trademark of Freelancer Technology Pty Limited (ACN 142 189 759)
Copyright © 2025 Freelancer Technology Pty Limited (ACN 142 189 759)
プレビューを読み込み中
位置情報へのアクセスが許可されました。
あなたのログインセッションの有効期限がきれ、ログアウトされました。もう一度ログインしてください。